Jasper Therapeutics Stock Price, News & Analysis (NASDAQ:JSPR) $0.51 -0.01 (-1.92%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.48▼$0.5350-Day Range$0.51▼$0.9352-Week Range$0.39▼$3.80Volume2.01 million shsAverage Volume272,043 shsMarket Capitalization$56.90 millionP/E RatioN/ADividend YieldN/APrice Target$5.96 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Jasper Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,069.1% Upside$5.96 Price TargetShort InterestBearish2.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$12,300 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.62) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector349th out of 942 stocksBiological Products, Except Diagnostic Industry57th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingJasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.96, Jasper Therapeutics has a forecasted upside of 1,069.1% from its current price of $0.51.Amount of Analyst CoverageJasper Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.30% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Jasper Therapeutics has recently increased by 1.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JSPR. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have bought 81.68% more of their company's stock than they have sold. Specifically, they have bought $12,300.00 in company stock and sold $6,770.00 in company stock.Percentage Held by InsidersOnly 3.90% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jasper Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jasper Therapeutics Stock (NASDAQ:JSPR)Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.Read More JSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JSPR Stock News HeadlinesNovember 30, 2023 | finanznachrichten.deJasper Therapeutics: Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous UrticariaNovember 30, 2023 | finance.yahoo.comJasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous UrticariaDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | msn.comJasper Therapeutics GAAP EPS of -$0.16 in-lineNovember 9, 2023 | benzinga.comJasper Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comJasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business ProgressNovember 9, 2023 | finance.yahoo.comJasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 8, 2023 | finance.yahoo.comJasper Therapeutics to Participate at Upcoming Medical and Investor ConferencesDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 2, 2023 | finance.yahoo.comJasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023November 1, 2023 | finance.yahoo.comJasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of DirectorsOctober 23, 2023 | thestreet.comJasper Therapeutics Inc.October 10, 2023 | finance.yahoo.comJasper Therapeutics, Inc.'s (NASDAQ:JSPR) high institutional ownership speaks for itself as stock continues to impress, up 25% over last weekOctober 10, 2023 | msn.comJasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria StudyOctober 9, 2023 | finance.yahoo.comJasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous UrticariaOctober 9, 2023 | finance.yahoo.comJasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023September 25, 2023 | markets.businessinsider.comJasper Therapeutics Appoints Herb Cross As New CFOSeptember 21, 2023 | finance.yahoo.comJasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific SymposiumSeptember 15, 2023 | finance.yahoo.comJasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare ConferenceAugust 12, 2023 | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 4, 2023 | finance.yahoo.comJasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 2, 2023 | finance.yahoo.comJasper Therapeutics Strengthens Management Team with Key AppointmentsJuly 5, 2023 | fool.comJasper Therapeutics (NASDAQ: JSPR)June 22, 2023 | finance.yahoo.comJasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeJune 21, 2023 | benzinga.comJasper Therapeutics Director Awarded $128K Worth of Stock OptionsJune 20, 2023 | finance.yahoo.comJasper Therapeutics Appoints Scott Brun, M.D., to its Board of DirectorsJune 20, 2023 | finance.yahoo.comJasper Therapeutics Appoints Scott Brun, M.D., to its Board of DirectorsSee More Headlines Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JSPR CUSIPN/A CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees35Year FoundedN/APrice Target and Rating Average Stock Price Target$5.96 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,069.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.86% Return on Assets-57.95% Debt Debt-to-Equity RatioN/A Current Ratio8.84 Quick Ratio8.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book0.54Miscellaneous Outstanding Shares111,575,000Free Float107,224,000Market Cap$56.90 million OptionableNot Optionable Beta1.91 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Ronald A. Martell (Age 61)President, CEO & Director Comp: $892.45kDr. Judith Anne Shizuru M.D. (Age 67)Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director Comp: $291.25kMr. Jeetinder Singh Mahal M.B.A. (Age 51)Chief Operating Officer Comp: $579.46kMr. Herbert C. Cross (Age 51)CFO & Corporate Secretary Dr. Luca Di Noto Ph.D.Senior Vice President of Technical OperationsMr. David Ku M.D.Vice President of Corporate Development, Portfolio Strategy & ManagementMr. Matthew FordVice President of Human ResourcesDr. Wendy Pang M.D.Ph.D., Senior Vice President of Research & Translational MedicineDr. Edwin Jonathan Tucker M.D. (Age 51)Chief Medical Officer Ms. Patricia CarlosSenior Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsCardiff OncologyNASDAQ:CRDFC4 TherapeuticsNASDAQ:CCCCCardiol TherapeuticsNASDAQ:CRDLAVROBIONASDAQ:AVROTurnstone BiologicsNASDAQ:TSBXView All CompetitorsInsiders & InstitutionsWalleye Capital LLCSold 14,000 shares on 11/21/2023Ownership: 0.000%Thomas G WiggansBought 10,000 shares on 11/20/2023Total: $6,300.00 ($0.63/share)Thomas G WiggansBought 10,000 shares on 11/16/2023Total: $6,000.00 ($0.60/share)Mariner LLCSold 62,247 shares on 11/13/2023Ownership: 0.589%Cowen AND Company LLCBought 200,393 shares on 11/9/2023Ownership: 0.181%View All Insider TransactionsView All Institutional Transactions JSPR Stock Analysis - Frequently Asked Questions Should I buy or sell Jasper Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares. View JSPR analyst ratings or view top-rated stocks. What is Jasper Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued 1 year price targets for Jasper Therapeutics' stock. Their JSPR share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.96 in the next twelve months. This suggests a possible upside of 1,069.1% from the stock's current price. View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts. How have JSPR shares performed in 2023? Jasper Therapeutics' stock was trading at $0.4829 on January 1st, 2023. Since then, JSPR stock has increased by 5.6% and is now trading at $0.51. View the best growth stocks for 2023 here. When is Jasper Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our JSPR earnings forecast. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. Who are Jasper Therapeutics' major shareholders? Jasper Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Mariner LLC (0.59%), Cowen AND Company LLC (0.18%), Forefront Analytics LLC (0.10%), Summit Trail Advisors LLC (0.06%) and Walleye Capital LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and William Lis. View institutional ownership trends. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:JSPR) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.